sur TME PHARMA N.V. (isin : NL0015000YE1)
TME Pharma's Semi-Annual Report and Financial Restructuring
TME Pharma N.V., a biotechnology firm based in Berlin, has released its semi-annual results. The company underwent a significant reorganization, transitioning to a leaner staffing model, which reduced costs substantially. This change coincided with the appointment of a new CEO, Diede van den Ouden, in June 2025.
The company raised €1.7 million through bond issuance in May 2025, followed by an additional €500,000 in August, highlighting investor confidence. Despite a reduction in workforce, TME Pharma continues to focus on its NOX A12 and NOX E36 assets, seeking partnerships and profitable ventures.
Financially, TME Pharma recorded a net loss of €2.1 million for H1 2025 but reduced losses compared to €3.2 million in H1 2024. Turnover reached €27k, up from zero the previous year. The cash position stands at €2.06 million, with financial visibility until May 2026.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TME PHARMA N.V.